BR112023017365A2 - Glicano e método para produzir medicamento contendo glicano - Google Patents

Glicano e método para produzir medicamento contendo glicano

Info

Publication number
BR112023017365A2
BR112023017365A2 BR112023017365A BR112023017365A BR112023017365A2 BR 112023017365 A2 BR112023017365 A2 BR 112023017365A2 BR 112023017365 A BR112023017365 A BR 112023017365A BR 112023017365 A BR112023017365 A BR 112023017365A BR 112023017365 A2 BR112023017365 A2 BR 112023017365A2
Authority
BR
Brazil
Prior art keywords
glycan
producing
new
biantennary
oligosaccharide
Prior art date
Application number
BR112023017365A
Other languages
English (en)
Portuguese (pt)
Inventor
Keisuke Suzuki
Ryusei ITOH
Tsuyoshi Ueda
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112023017365A2 publication Critical patent/BR112023017365A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044Pyrrole radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18Acyclic radicals, substituted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023017365A 2021-03-12 2022-03-11 Glicano e método para produzir medicamento contendo glicano BR112023017365A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021040164 2021-03-12
PCT/JP2022/010851 WO2022191313A1 (ja) 2021-03-12 2022-03-11 糖鎖及び糖鎖を含む医薬品の製造方法

Publications (1)

Publication Number Publication Date
BR112023017365A2 true BR112023017365A2 (pt) 2023-10-03

Family

ID=83228168

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017365A BR112023017365A2 (pt) 2021-03-12 2022-03-11 Glicano e método para produzir medicamento contendo glicano

Country Status (9)

Country Link
US (1) US20240279364A1 (https=)
EP (1) EP4306546A4 (https=)
JP (2) JP7721635B2 (https=)
KR (1) KR20230157983A (https=)
CN (2) CN121021596A (https=)
BR (1) BR112023017365A2 (https=)
CA (1) CA3212691A1 (https=)
IL (1) IL305816A (https=)
WO (1) WO2022191313A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250064682A (ko) * 2022-09-09 2025-05-09 다이이찌 산쿄 가부시키가이샤 신규 올리고당, 그 올리고당의 제조 중간체, 및 그것들의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051702A (ja) * 1983-08-30 1985-03-23 Rikagaku Kenkyusho 複合多糖およびその製造法
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1996002255A1 (en) 1994-07-15 1996-02-01 Taiyo Kagaku Co., Ltd. Medicinal composition containing sialic acid derivative
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU2002311919B8 (en) 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
WO2004008099A2 (en) 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス, インコーポレイテッド 抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
JP2009155353A (ja) * 2006-03-30 2009-07-16 Yokohama City Univ 糖鎖化合物の製造方法
BRPI0816094A2 (pt) 2007-08-30 2015-03-03 Daiichi Sankyo Co Ltd Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
US8809496B2 (en) 2009-09-03 2014-08-19 The Noguchi Institute Production method of 11-sugar sialylglycopeptide
US10851174B2 (en) * 2011-03-03 2020-12-01 University Of Maryland, Baltimore Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof
WO2012135049A1 (en) * 2011-03-25 2012-10-04 University Of Georgia Research Foundation, Inc. Compounds and methods for chemical and chemo-enzymatic synthesis of complex glycans
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
TW201442721A (zh) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
TW201534613A (zh) 2013-06-28 2015-09-16 Daiichi Sankyo Co Ltd 寡糖胜肽之純化方法
WO2015080603A1 (en) * 2013-11-28 2015-06-04 Antony John Fairbanks Glycoproteins
AU2014371934B2 (en) 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
US11559581B2 (en) 2015-01-09 2023-01-24 Oxford University Innovation Limited Antibody conjugates and methods of making the antibody conjugates
WO2017110984A1 (ja) 2015-12-25 2017-06-29 第一三共株式会社 限外ろ過膜を用いたオリゴ糖ペプチドの精製法
WO2018003983A1 (ja) 2016-07-01 2018-01-04 第一三共株式会社 hANP-Fc含有分子コンジュゲート
JP6342968B2 (ja) * 2016-07-25 2018-06-13 株式会社伏見製薬所 糖誘導体の製造方法及び新規糖誘導体
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體-藥物結合物及其用途
NZ762505A (en) 2017-09-29 2026-03-27 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
EP3848054B1 (en) 2018-09-06 2025-01-29 Daiichi Sankyo Company, Limited Antibody-drug conjugates of cyclic dinucleotide derivatives

Also Published As

Publication number Publication date
WO2022191313A1 (ja) 2022-09-15
CA3212691A1 (en) 2022-09-15
CN121021596A (zh) 2025-11-28
JP2025160360A (ja) 2025-10-22
CN116917341B (zh) 2025-09-23
JPWO2022191313A1 (https=) 2022-09-15
US20240279364A1 (en) 2024-08-22
KR20230157983A (ko) 2023-11-17
IL305816A (en) 2023-11-01
JP7721635B2 (ja) 2025-08-12
CN116917341A (zh) 2023-10-20
EP4306546A4 (en) 2025-06-18
EP4306546A1 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
Li et al. Strategies for chemoenzymatic synthesis of carbohydrates
Chen et al. One-pot three-enzyme synthesis of UDP-GlcNAc derivatives
Chang et al. Synthesis of the Heparin‐Based Anticoagulant Drug Fondaparinux
Mahalingam et al. Cellular adhesion responses to the heparin-binding (HepII) domain of fibronectin require heparan sulfate with specific properties
BR112021012401A2 (pt) Acetil-transferases inovadoras
US20050239741A1 (en) Novel synthetic ganglioside derivatives and compositions thereof
BR112016021909A2 (pt) solução de reação, método de produção de póli alfa-1,3-glucano insolúvel e póli alfa-1,3-glucano isolado
BR112012005737A2 (pt) método para a produção de ácido 3-hidróxi-3-metilbutírico a partir de acetona e um composto acetila ativado.
BR112012032744A2 (pt) moléculas de rna e usos das mesmas.
BR112023017365A2 (pt) Glicano e método para produzir medicamento contendo glicano
BR112018004538A2 (pt) processo para produção de pelo menos um de fibra celulósica, arabinoxilano solúvel em água, arabinoxilano ramificado de baixo peso molecular ou arabinoxilano de baixo peso molecular, uso de uma composição, ingrediente, composição, e, fibra
BR112012015695A2 (pt) xilanase termoestável para a hidrólise seletiva de polissacarídeos contendo pentose
Slámová et al. Engineered N-acetylhexosamine-active enzymes in glycoscience
BR112014030857A2 (pt) processo de produção de ácido adípico a partir de 1,6-hexanodiol
BR112013025819A2 (pt) promotor específico para semente em algodão
BR112021025681A2 (pt) Método para preparar uma pasta de fiação de fibra de celulose regenerada por um método de solvente processo e sistema
Uchinashi et al. Practical and efficient method for α-sialylation with an azide sialyl donor using a microreactor
Huang et al. Multi-enzyme one-pot strategy for the synthesis of sialyl Lewis X-containing PSGL-1 glycopeptide
CL2023002544A1 (es) Glicósidos de esteviol xilosilados y métodos enzimáticos para la producción
BR112018006278A2 (pt) proteína lisossômica modificada e produção da mesma
Abreu et al. Tunicate heparan sulfate enriched in 2-sulfated β-glucuronic acid: structure, anticoagulant activity, and inhibitory effect on the binding of human colon adenocarcinoma cells to immobilized P-selectin
JP2012158526A (ja) マンノオリゴ糖の製造法
NO20011089L (no) Fremgangsmåte for produksjon av sialylerte oligosakkarider
CN103539827B (zh) 一种合成对甲氧基三苯基α-S-(1→6)-D-葡萄二糖的方法
Liao et al. Stereoselective Synthesis of 2‐Deoxy Glycosides via a Novel 2‐O‐Resided (o‐Alkynyl) benzoate‐Initiated 1, 2‐Sulfur Migration/Glycosylation and Desulfurization Protocol as well as Mechanism Elucidation

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]